Compare BIO-TECHNE Corp (TECH) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Ultra Short Bond ETF — how do they compare? BIO-TECHNE Corp trades at $72.06 (market cap $11.24B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Ultra Short Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VUSB | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.29 | $50.03 |
52-Week Low | $43.31 | $49.60 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VUSB trades at $49.66, up 0.04% on the day, with a bearish technical signal driven by moving averages and ADX readings. Recent dividends include $0.18 paid on July 6, 2026, and $0.17 scheduled for August 5, 2026. Financial ratios such as P/E and ROE are unavailable in the current data, limiting fundamental assessment.
The outlook is cautious due to bearish technical indicators and incomplete financial data. Risks include interest rate sensitivity, as highlighted by recent Fed commentary, and reliance on short-term bond performance. Investors should await updated financial disclosures for a clearer fundamental picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
